The main goals of therapy for patients with heart failure with preserved ejection fraction are to address the signs and symptoms of heart failure, improve quality of life, and reduce the risk of ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

Patients with heart failure with preserved ejection fraction (HFpEF) present with non-specific symptoms ... The intervention will focus on improving diagnostic process, decreasing physician burden and ...

The new approach is designed to create a connection between the left and right atrial chambers of the heart in a single ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

which minimized the confounder that patients with systolic heart failure whose ejection fraction might have improved with concurrent treatments were enrolled into this study. I-PRESERVE ...